December 13, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Christopher Edwards |
Jordan Nimitz
Kevin Vaugh
Christine Wong
| Re: | Bionomics Limited |
Registration Statement on Form F-1
Registration No. 333-261280
Acceleration Request
Requested Date: December 15, 2021
Requested Time: 4:00 PM, Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Evercore Group L.L.C. and William Blair & Company, L.L.C, as representatives of the several underwriters, hereby join Bionomics Limited in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form F-1 (File No. 333-261280) (the “Registration Statement”) to become effective on December 15, 2021, at 4:00 PM, Eastern Daylight Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
| Very truly yours, | ||
| Evercore Group L.L.C. | ||
| By: | /s/ Ed Baxter | |
| Name: | Ed Baxter | |
| Title: | Senior Managing Director | |
| William Blair & Company, L.L.C. | ||
| By: | /s/ Steve Maletzky | |
| Name: | Steve Maletzky | |
| Title: | Head of Equity Capital Markets | |
cc: Errol De Souza, Ph.D., Bionomics Limited
Benjamin K. Marsh, Goodwin Procter LLP
Nathan Ajiashvili, Latham & Watkins LLP
Michael E. Sullivan, Latham & Watkins LLP
Cheston J. Larson, Latham & Watkins LLP
[Signature Page to Acceleration Request]